A logo

Agilent Technologies Inc. (A)

$112.74

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on A

Market cap

$31.86B

EPS

4.53

P/E ratio

24.9

Price to sales

4.52

Dividend yield

0.905%

Beta

1.21854

Price on A

Previous close

$112.90

Today's open

$112.83

Day's range

$111.96 - $114.73

52 week range

$107.07 - $160.27

Profile about A

CEO

Padraig Mcdonnell

Employees

18000

Headquarters

Santa Clara, CA

Exchange

New York Stock Exchange

Shares outstanding

282602317

Issue type

Common Stock

A industries and sectors

Healthcare

Biotechnology & Life Sciences

News on A

Agilent to Participate in Jefferies Global Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 9:20 EDT on Wednesday, June 3, 2026, in New York City. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global lead.

news source

Business Wire • May 11, 2026

news preview

Agilent Names Michael Buckner as Chief Legal Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. “We are thrilled to welcome Michael to the Agilent team,” said Padraig McDonnell, Agilent president an.

news source

Business Wire • May 4, 2026

news preview

Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.

news source

Business Wire • Apr 28, 2026

news preview

Carillon Scout Mid Cap Fund Q1 2026 Portfolio Review

Hyperscalers led the trend while emerging customer groups such as smaller AI-focused cloud data center operators grew rapidly. Teradyne benefits from increasing semiconductor test complexity for AI accelerator, networking, and memory chips. Agilent lagged in the first quarter despite posting solid headline results, as investors focused on a few softer underlying trends.

news source

Seeking Alpha • Apr 28, 2026

news preview

Axion BioSystems and Agilent Technologies Resolve Litigation

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, Inc., a leading provider of live-cell analysis technologies, today announced that Agilent Technologies, Inc. and Axion BioSystems have fully resolved the issues in the two lawsuits between them, pending in the United States District Court for the District of Delaware, pursuant to the terms of a confidential settlement agreement. Neither party has admitted liability for the other party's claims or counterclaims or otherwise agreed to the positions asse.

news source

Business Wire • Apr 21, 2026

news preview

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f.

news source

Business Wire • Apr 15, 2026

news preview

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea.

news source

Business Wire • Apr 1, 2026

news preview

Why Is Agilent (A) Down 6.2% Since Last Earnings Report?

Agilent (A) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Mar 27, 2026

news preview

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.

news source

Business Wire • Mar 26, 2026

news preview

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda.

news source

Business Wire • Mar 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Agilent Technologies Inc.

Open an M1 investment account to buy and sell Agilent Technologies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in A on M1